C5AR1 and granulomatosis with polyangiitis: Building on these observations, this larger phase 3 trial, with 1-year treatment duration and observation, aims to provide evidence for the effectiveness of C5aR inhibition for the treatment of ANCA-associated vasculitis, with potential to fundamentally change the treatment paradigm of MPA and GPA.